Dispatch Bio has dosed the first participant in a Phase I clinical trial evaluating the safety and efficacy of DISP-10 in adult participants with advanced gastrointestinal (GI) cancers, including colorectal cancer, gastric adenocarcinoma, oesophageal adenocarcinoma, and gastroesophageal adenocarcinoma.  

The participant was treated with both DV-10 and ide-cel components of DISP-10 and completed the protocol-defined dose-limiting toxicity (DLT) evaluation period.  

Additionally, DISP-10 has received Fast Track designation from the US Food and Drug Administration (FDA) for the treatment of advanced GI cancers.  

Mauro Avanzi, Chief Medical Officer of Dispatch, commented: “We look forward to advancing this study as we work to overcome the longstanding limitations of treating solid tumours with immunotherapy, including lack of a safe and homogeneously expressed target antigen, a narrow therapeutic window, and an inhibitory tumour microenvironment. DISP-10 aims to address these barriers with our novel approach.” 

DISP-10 consists of two components. The first is DV-10, a tumour-specific virus engineered to deliver a modified B cell maturation antigen (dBCMA), along with IL-18 and CXCL9, to “paint” a synthetic antigen onto tumour cells, remodel the tumour microenvironment to support T cell function, and help enhance T cell trafficking into tumours.  

The second component is ide-cel, Bristol Myers Squibb’s BCMA-directed CAR-T cell therapy. By leveraging components with significant clinical experience, Dispatch aims to proceed rapidly through clinical development. 

“Patients with advanced GI cancers can face a challenging prognosis, often measured in a handful of months with limited treatment options beyond chemotherapy,” said Marwan Fakih, Division Chief, GI Medical Oncology and Deputy Director, City of Hope Comprehensive Cancer Center. “There is a clear need for new approaches, and the initiation of this study with DISP-10 is an important step toward exploring a novel strategy that may expand the reach of immunotherapy treatments for patients.”